Investors may find better financial performance in MannKind Corporation (MNKD)

Currently, MannKind Corporation [MNKD] is trading at $3.17, down -1.25%. An important factor to consider is whether the stock is rising or falling in short-term value. The MNKD shares have lost -15.24% over the last week, with a monthly amount drifted -18.30%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 21, September 2022, MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference. In a post published today on Yahoo Finance, MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

From an analyst’s perspective:

MannKind Corporation [NASDAQ: MNKD] stock has seen the most recent analyst activity on May 14, 2021, when RBC Capital Mkts initiated its Sector Perform rating and assigned the stock a price target of $5. Previously, Oppenheimer started tracking the stock with Outperform rating on December 24, 2019, and set its price target to $2.50. On October 25, 2019, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $3 on May 14, 2019. SVB Leerink initiated its recommendation with a Outperform and recommended $3 as its price target on March 04, 2019. SVB Leerink started tracking with a Outperform rating for this stock on February 22, 2019, and assigned it a price target of $3. In a note dated February 28, 2018, Maxim Group downgraded an Sell rating on this stock but restated the target price of $1.

This stock has fluctuated between a low of $2.49 and a high of $5.44 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $6.00 within the next 12 months. MannKind Corporation [NASDAQ: MNKD] shares were valued at $3.17 at the most recent close of the market. An investor can expect a potential return of 89.27% based on the average price forecast.

Analyzing the MNKD fundamentals

Recent quarter sales for MannKind Corporation [NASDAQ:MNKD] were 18.89 billion which represents -18.90% decline.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.09 points at the first support level, and at 3.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.24, and for the 2nd resistance point, it is at 3.32.

MannKind Corporation [MNKD] reported earnings per share of -$0.1 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.11 per share as compared to estimates of -$0.07 per share, a difference of $-0.04 representing a surprise of -57.10%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for MannKind Corporation [NASDAQ:MNKD] is 3.20.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 8 insider purchases totaling 27,038 shares and 2 insider sales totaling 4,615 shares over the past 3 months. Recent insider trading involved Thomson David, EVP Genl Counsel & Secretary, that happened on Aug 29 when 7000.0 shares were sold. EVP Endocrine Business Unit, Galindo Alejandro completed a deal on Aug 22 to sell 4615.0 shares. Meanwhile, EVP Endocrine Business Unit Galindo Alejandro bought 5000.0 shares on Jul 31.